Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 247 clinical trials
Cancer and Blood Pressure Management CARISMA Study

the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This study is being done to find out if a systolic blood pressure to a target of less than 120 mmHg

  • 0 views
  • 13 Mar, 2021
  • 1 location
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

The purpose of this study is to determine if adding Ruxolitinib to a Tyrone Kinase Inhibitor (TKI), prior to a second attempt at stopping a TKI will lead to prolonged treatment free remission

  • 0 views
  • 07 Mar, 2021
  • 9 locations
Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER1, HER2 and HER4 receptors. This study is a single-arm, prospective, single-center clinical study of pyrotinib plus fulvestrant

erbb2
breast cancer
pyrotinib
cancer
trastuzumab
  • 3 views
  • 24 Jan, 2021
  • 1 location
Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma

Apatinib mesylate is a multitarget receptor tyrosine kinase inhibitor. This trial is to evaluate the efficacy and safety of apatinib mesylate combined with doxorubicin and ifosfamide in the

angiosarcoma
fibrosarcoma
ifosfamide
metastasis
liposarcoma
  • 0 views
  • 26 Jan, 2021
  • 1 location
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a

  • 0 views
  • 03 Feb, 2021
  • 3 locations
Study of TL-895 in Subjects With Myelofibrosis

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must be relapsed/refractory

  • 0 views
  • 27 Mar, 2021
  • 5 locations
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

To assess the efficacy and safety of D-0316 versus Icotinib, a standard of care epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with locally advanced or

EGFR
epidermal growth factor receptor
lung carcinoma
icotinib
kinase inhibitor
  • 0 views
  • 24 Jan, 2021
  • 2 locations
Stereotactic Body Radiotherapy for the Treatment of OPD

patients with mutation positive advanced NSCLC with oligoprogressive disease (OPD) following initial response to a Tyrosine Kinase Inhibitor (TKI).

progressive disease
kinase inhibitor
stereotactic body radiation therapy
metastasis
tyrosine
  • 19 views
  • 22 Jan, 2021
  • 6 locations
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

chemoembolization
solid tumors
dotatate
neuroendocrine tumor
sunitinib
  • 190 views
  • 14 Apr, 2021
  • 255 locations
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours are Epidermal Growth Factor Receptor Mutation and T790M Mutation Positive

lung cancer
EGFR
epidermal growth factor receptor
lung carcinoma
erlotinib
  • 2 views
  • 23 Jan, 2021
  • 1 location